 SPARTA, N.J., July 22, 2021 GLOBE NEWSWIRE -- PLx Pharma Inc. NASDAQ: PLXP PLx or the Company, a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuardTM drug delivery platform to provide more effective and safer products, with its lead products VAZALORETM 325 mg and VAZALORETM 81 mg referred to together as VAZALORE, announced today that the Company will release its 2021 second quarter financial results on Friday, August 6, 2021, before the U.S. financial markets open. 